Errata

Validation of the 

Medaka Multigeneration Test:

Integrated Summary Report

U.S. Environmental Protection Agency

Endocrine Disruptor Screening Program

Washington, D.C.

June 21, 2013

|
Forward

A portion of the medaka data provided in the MMT ISR was originally analyzed using the 

statistical package StatCHARRMS that was recently found to have an error in the one-way 

ANOVA module. In that module the replicate data was not considered in the statistical analyses. 

Thus, the statistical unit of analysis became the individual animal rather than the tank which 

resulted in erroneous estimates of the following: biological variances, variances on effects due to 

treatment, and variances on estimates of biological means. It also introduces the possibility of 

confounding treatment effects with possible tank effects. The analyses in the other two modules 

of StatCHARRMS, a repeated measure ANOVA, and a pathology analysis module (RSCABS), 

correctly incorporate the replicate structure of the test protocols. It should be noted that the recoding of the one-way ANOVA module in the open source ‘R’ version of StatCHARRMS being 

developed by the Agency did not have this error and correctly identifies the statistical sampling 

unit as the tank, when specified, and not the individual organism. 

Specifically, with respect to the MMT assay the StatCHARRMS error only affected the analysis 

of AOP-diagnostic endpoints measured in the subadults (i.e., vitellogenin, secondary sex 

characters, and growth). The statistical analysis of adult endpoints such as the apical reproductive 

endpoints, and endocrine diagnostic endpoints of AOPs such as pathology were not affected. The 

statistics associated with the fecundity endpoint in all the MMT studies in the ISR were not 

affected, and the power analysis and the MRT recommendations remain unaffected. 

The MMT study data for the affected subadult endpoints of vitellogenin, secondary sex 

characters, and growth from all the EPA- and interlaboratory-run tests, i.e., octylphenol, 

trenbolone, CMP, and vinclozolin, were reanalyzed to correct for the error. For the Japanese 

MMT studies, i.e., 17β-estradiol, o,p′-DDT, 4-t-octylphenol, and tamoxifen, the original 

statistical analysis of the subadult endpoints, as performed by the Japanese scientists, have been 

incorporated into the corrected analysis.

The reanalysis most often resulted in no changes in the LOEC for any particular biomarker 

measurement. However, the LOECs for some of the biomarker datasets, as a result of using the 

aquarium as the unit of replication rather than the individual fish, did in fact change in the 

reanalysis. The most common changes were to move the LOEC one treatment level higher. In a 

few instances, the LOEC moved up more than one treatment level. A few decreases in the LOEC 

level also occurred. These changes were observed in instances where the treatment means were 

only slightly different (either higher or lower) than controls and no clear dose response was 

evident.

The overall effect of data reanalysis indicates that while biological variability was somewhat 

greater than indicated in the initial analyses for endpoints measured in subadult medaka, the 

effects were minor, and do not impact assay performance, recommended endpoints to be 

measured, or overall conclusions for each AOP, and the overall conclusions for each chemical 

tested remain the same as in the ISR. Thus, while the reanalysis showed that the sensitivity of the 

diagnostic endpoints was reduced in some cases, this reduction in sensitivity does not impact the 

ability of the proposed testing protocols to detect endocrine mediated AOPs in the assays. The 

utility of the assays for measuring dose-response for endocrine mediated toxicities in EDSP Tier 

2 testing is not affected. The EPA presentations on the MMT/MRT that will be given during the 

SAP will acknowledge and address this issue. 

The remainder of this erratum provides corrected summary tables and graphs for Appendices C 

and H of the MMT ISR. All the tables describing the LOECs for all the MMT endpoints have 
been modified to reflect the corrections to the subadult endpoints. For the EPA- and 

Interlaboratory-run studies, the changes reflect the result of reanalysis of the endpoints data. For 

the Japanese MMT studies, (17β-Estradiol, o,p′-DDT, 4-t-Octylphenol and Tamoxifen from the 

CERI and NIES labs respectively), the changes reflect the original Japanese-performed statistical 

analysis of the subadult endpoint data. The modified tables and graphs are attached to the end of 

this Erratum.

For each MMT, two tables are presented, the original table from either Appendix C or H 

MMT Summary Reports of the MMT ISR, and the revised table. All revisions are 

highlighted in yellow in the revised table. The graphs that were changed follow the 

revised LOEC summary table for each test chemical. The changed locations for 

significance indicators are specified in yellow boxes. A blank box indicates the removal 

of the significance indicator; and a yellow box with an * indicates the new LOEC. 

A narrative describing the changes for each MMT chemical follow.

17β-Estradiol CERI

There was only one change to the Summary LOEC table. In the original analysis the 

LOEC for a reduction in the anal fin papillae in F1 XY subadults was 2.8 ng/L. The 

corrected LOEC for this endpoint, as specified in the statistical analysis preformed by the 

Japanese, is two dose levels higher at 28 ng/L.

4-t-Octylphenol MED

There were three changes in the Summary LOEC table for octylphenol MED. For anal fin 

papillae, the LOEC for F1 XY subadults changed by one treatment level from 25 μg/L to 

51 μg/L. The LOECs for Vtg in both XY and XX in F1 subadults increased by a single 

dose level. The XY LOEC increased from 25 μg/L to 51 μg/L and the XX LOEC 

increased from 51 μg/L to 102 μg/L, Finally for F2 XX subadults, no LOEC could be 

determined > 51 μg/L, while in the initial incorrect analysis, it was 51 μg/L.

4-t-Octylphenol NIES

There were four changes in the Summary LOEC table for octylphenol NIES. Growth 

LOECs in F2 subadults were greater than the highest treatment level in this generation 

(>50 μg/L) as reported by the Japanese, instead of the incorrectly reported 25 μg/L for 

weight and 6.25 μg/L for length. Anal fin papillae in F2 XY fish also was initially 

reported by the Japanese as greater than the highest treatment (>50 μg/L) instead of the 

incorrectly calculated LOEC of 25 μg/L. Finally, the Vtg LOEC for F1 XY fish changed 

by one treatment level from 25 μg/L down to 12.5 μg/L.

o,p′-DDT CERI 

The LOECs, as reported by the Japanese, are identical to the Agency’s original calculated 

LOECs.

4-Chloro,3-methyl phenol (CMP) MED

There were four changes in the Summary LOEC table for CMP MED. Three of them are 

related to growth. The LOEC initially calculated for both weight and length of F1 XY 

fish was 165 μg/L (the second highest concentration tested) which was recalculated as 
being higher than 345 μg/L, the highest concentration tested. The initial analysis was 

unable to determine a LOEC for length in F2 XX fish, but the reanalysis calculated a 

LOEC of 345 μg/L, the highest concentration tested. The last change was in the LOEC 

for Vtg in F2 XX fish, which initially was 345 μg/L, but upon reanalysis, the LOEC was 

higher than the highest concentration of 345 μg/L. 

Tamoxifen NIES

There were 6 changes in the Summary LOEC table for tamoxifen NIES from those 

erroneously calculated by the Agency and those initially reported by Japanese 

researchers. Five of the six were in the growth parameters of weight and length in which 

the initial LOEC was 20 μg/L and the reanalyzed LOEC was greater than the highest 

concentration tested (20 μg/L). This situation was present in the following of F1: weight 

for both XX and XY fish, and length for XY fish. It was also present in the following of 

F2: weight and length of XX fish. In addition, the LOEC for Vtg in F2 XY fish increased 

one treatment level from 1.3 μg/L to 2.5 μg/L. 

Trenbolone MED

There were two changes in the Summary LOEC table for trenbolone MED. The LOEC 

for weight of XX fish in F1 increased one treatment level from 32 ng/L to 84 ng/L. 

Likewise, the LOEC for Vtg of XX fish in F1 increased one treatment level from 32 ng/L 

to 84 ng/L.

Prochloraz MED

There were four changes in the Summary LOEC table for prochloraz MED. The LOEC 

for F2 XY weight changed from 5 μg/L (the lowest treatment) to greater than 25 μg/L, the 

highest treatment. Similarly, the LOEC for F2 XY length changed from 9 μg/L to greater 

than 25 μg/L, the highest treatment. Also, the F2 XX length changed one treatment level 

from 9 μg/L to 5 μg/L. The means for these growth parameters were only slightly lower 

than control means across all treatments, and there was little indication of a dose 

response, therefore it is not surprising that the reanalysis, at times, changed the LOECs 

both multiple treatment levels. Finally the LOEC for anal fin papillae of F2 XY fish 

changed from greater than 25 μg/L (the highest concentration still with fish) to 9 μg/L

Vinclozolin MED

There were two changes in the Summary LOEC table for vinclozolin MED. The LOEC 

for anal fin papillae of F1 XY fish increased a single treatment level from 17 μg/L to 33 

μg/L. The second change was in the LOEC for F1 Vtg in XY fish which initially was 

greater than 136 μg/L (the highest concentration with fish present), but was recalculated 

to be 33 μg/L. 

Vinclozolin Lab 1

There were four changes in the Summary LOEC table for vinclozolin from Lab 1 of the 

interlab. Of these, three of them involved growth parameters. Weight for both female 

and male fish in F1 initially had a LOEC of 82 μg/L, which upon reanalysis changed to a 

LOEC greater than the highest concentration in the test, 197 μg/L. In addition, weight for 

F2 female fish was initially reported as 31 μg/L, but upon reanalysis changed to a 
LOEC greater than the highest concentration in the test, 197 μg/L. Lastly, the LOEC for 

anal fin papillae in F2 males increased two treatment levels from 5 μg/L to 31 μg/L. 

Vinclozolin Lab 2

There were four changes in the Summary LOEC table for vinclozolin from Lab 2 of the 

interlab. Weight for XY fish in F1 initially had a LOEC of 62 μg/L, which upon 

reanalysis changed to 360 μg/L, two treatment levels. Weight for XX fish in F1 initially 

had a LOEC of 12 μg/L, which upon reanalysis changed to 360 μg/L. Also, weight for 

XY fish in F2 initially had a LOEC of 62 μg/L, which upon reanalysis changed to 360 

μg/L. Finally, Vtg in F1 XX fish initially had a reported LOEC of 360 μg/L, but upon 

reanalysis, the LOEC was in fact greater than 360 μg/L, the higher concentration tested. 

Vinclozolin Lab 3

The LOECs, as calculated in the reanalysis, are identical to the Agency’s original 

calculated LOECs.
Original Incorrect Summary Table (Table 1) for 17β-estradiol (Appendix H, page 6).

Corrected Summary Table (Table 1) for 17β-estradiol (Appendix H, page 6).

Any changes are highlighted with yellow boxes.

E2 MMT LOEC Summary E2 (ng/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult subadult adult adult adult 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 0.9 0.11

Weight LOEC>84 28↑ 3 2.8 0.35

Length LOEC>84 28↑ 4 8.9 1.04

Survival LOEC>84 LOEC>84 5 28 2.9

Hatch LOEC>84 28↓ 6 84 7.1

Papillae 2.8 ↓ 28↓ LOEC>84 28↓ LOEC>28

Vtg 28 ↑ 84 ↑ 28 ↑ 8.9 ↑ 28↑ LOEC>84 28↑ LOEC>84 28↑ LOEC>28

Gonad Phenotype 28 ↑ LOEC>84 28 ↑ LOEC>28 28↑ LOEC>84 28↑ LOEC>28

Fecundity LOEC>84 28↓ LOEC>28

Fertility LOEC>84 28↓ 28↓

Highest Conc 84 28 84 84 28

E2 MMT LOEC Summary E2 (ng/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult subadult adult adult adult 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 0.9 0.11

Weight LOEC>84 28↑ 3 2.8 0.35

Length LOEC>84 28↑ 4 8.9 1.04

Survival LOEC>84 LOEC>84 5 28 2.9

Hatch LOEC>84 28↓ 6 84 7.1

Papillae 28↓ 28↓ LOEC>84 28↓ LOEC>28

Vtg 28 ↑ 84 ↑ 28 ↑ 8.9 ↑ 28↑ LOEC>84 28↑ LOEC>84 28↑ LOEC>28

Gonad Phenotype 28 ↑ LOEC>84 28 ↑ LOEC>28 28↑ LOEC>84 28↑ LOEC>28

Fecundity LOEC>84 28↓ LOEC>28

Fertility LOEC>84 28↓ 28↓

Highest Conc 84 28 84 84 28
E2 F1 Subadult XY SSC CERI MMT

0 0.9 2.8 8.9 28 84

Concentration (ng/L)

0

20

40

60

80

100

Anal Fin Papillae (#/fin)

*

*

*

*

E2 F1 Subadult XY SSC CERI MMT

0 0.9 2.8 8.9 28 84

Concentration (ng/L)

0

20

40

60

80

100

Anal Fin Papillae (#/fin)

*

*

*

*
Original Incorrect Summary Table (Table 1) for 4-t-octyphenol MED (Appendix H, page 25).

Corrected Summary Table (Table 1) for 4-t-octyphenol MED (Appendix H, page 25).

4tOP MMT LOEC Summary 4tOP (ug/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult (7 wpf) subadult (7 wpf) adult (15 wpf) adult (15 wpf) adult (15 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 6 0.6

Weight LOEC>102 LOEC>102 LOEC>51 LOEC>51 LOEC>102 JT: 102 ↑ JT: 51 ↑ LOEC>102 LOEC>51 LOEC>51 3 13 1.5

Length LOEC>102 LOEC>102 LOEC>51 LOEC>51 LOEC>102 JT:102 ↑ JT: 13 ↑ LOEC>102 LOEC>51 LOEC>51 4 25 2.6

Survival LOEC>102 LOEC>51 LOEC>102 LOEC>102 LOEC>102 LOEC>102 LOEC>51 LOEC>51 5 51 5.6

Hatch 102 ↓ LOEC>51 6 102 8.5

Papillae D,JT: 25 ↓ LOEC>102 Du, JT: 13 ↓ LOEC>51 LOEC>102 LOEC>102 D,JT:102 ↓ LOEC>102 JT:13 ↓ LOEC>51

Vtg Du, JT: 25 ↑ Du, JT: 51 ↑ Du, JT: 25 ↑ JT: 51 ↑ D,JT: 51 ↑ LOEC>102 D, JT: 51 ↑ LOEC>102 51 ↑ LOEC>51

Gonad 

Phenotype 25 ↑ LOEC>102 25 ↑ LOEC>51 LOEC>102 LOEC>102 13 ↑ LOEC>102 51 ↑ LOEC>51

Fecundity LOEC>102; trend ↓ 102 ↓ 51↓; not by wk

Fertility LOEC>102; trend ↓ 102 ↓ 51↓; esp wk11

Highest 

Conc

102 51 102 102 51

4tOP MMT LOEC Summary 4tOP (ug/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult (7 wpf) subadult (7 wpf) adult (15 wpf) adult (15 wpf) adult (15 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 6 0.6

Weight LOEC>102 LOEC>102 LOEC>51 LOEC>51 LOEC>102 JT: 102 ↑ JT: 51 ↑ LOEC>102 LOEC>51 LOEC>51 3 13 1.5

Length LOEC>102 LOEC>102 LOEC>51 LOEC>51 LOEC>102 JT:102 ↑ JT: 13 ↑ LOEC>102 LOEC>51 LOEC>51 4 25 2.6

Survival LOEC>102 LOEC>51 LOEC>102 LOEC>102 LOEC>102 LOEC>102 LOEC>51 LOEC>51 5 51 5.6

Hatch 102 ↓ LOEC>51 6 102 8.5

Papillae D: 51↓ LOEC>102 D: 13 ↓ LOEC>51 LOEC>102 LOEC>102 D,JT:102 ↓ LOEC>102 JT:13 ↓ LOEC>51

Vtg D: 51 D: 102 ↑ D: 25 ↑ LOEC>51 D,JT: 51 ↑ LOEC>102 D, JT: 51 ↑ LOEC>102 51 ↑ LOEC>51

Gonad 

Phenotype 25 ↑ LOEC>102 25 ↑ LOEC>51 LOEC>102 LOEC>102 13 ↑ LOEC>102 51 ↑ LOEC>51

Fecundity LOEC>102; trend ↓ 102 ↓ 51↓; not by wk

Fertility LOEC>102; trend ↓ 102 ↓ 51↓; esp wk11

Highest 

Conc

102 51 102 102 51
4tOP F1 Subadult Vitellogenin MED MMT

Concentration (ug/L)

Vtg mRNA Relative to Controls

0 6 13 25 51 102

0

100

200

300

400

500

 XY

 XX

D, JT D, JT

D, JT

D, JT

D, JT

4tOP F1 Subadult Vitellogenin MED MMT

Concentration (ug/L)

Vtg mRNA Relative to Controls

0 6 13 25 51 102

0

100

200

300

400

500

 XY

 XX

D, JT D, JT

D, JT

D, JT

D, JT
4tOP F2 Subadult Vitellogenin MED MMT

Concentration (ug/L)

Vtg mRNA Relative to Controls

0 6 13 25 51 102

0

100

200

300

400

500

 XY

 XX

JT, Tam

D, JT

D, JT

4tOP F2 Subadult Vitellogenin MED MMT

Concentration (ug/L)

Vtg mRNA Relative to Controls

0 6 13 25 51 102

0

100

200

300

400

500

 XY

 XX

JT, Tam

D, JT

D, JT

D

D

D
4tOP F1 Subadult SSC MED MMT

Concentration (ug/L)

Anal Fin Papillae (#/fin)

06 13 25 51 102

0

10

20

30

40

50

60

70

80

90

 XY

 XX

D,JT

D,JT

D,JT

4tOP F1 Subadult SSC MED MMT

Concentration (ug/L)

Anal Fin Papillae (#/fin)

06 13 25 51 102

0

10

20

30

40

50

60

70

80

90

 XY

 XX

D,JT

D,JT

D,JT
Original Incorrect Summary Table (Table 1) for 4-t-octyphenol NIES (Appendix H, page 46).

Corrected Summary Table (Table 1) for 4-t-octyphenol NIES (Appendix H, page 46).

4tOP MMT LOEC Summary 4tOP (ug/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult (8 wpf) subadult (8 wpf) adult (15 wpf) adult (15 wpf) adult (15 wpf) 1 0 na

XY XX XY XX XY XX XY XX XY XX 2 6.25 na

Weight LOEC>100 25 ↑ 3 12.5 na

Length LOEC>100 6.25 ↑ 4 25 na

Survival LOEC>100 ? LOEC>50 ? LOEC>100 LOEC>100 LOEC>50 LOEC>50 5 50 na

Hatch LOEC>100 LOEC>50 6 100 na

Papillae 6.25 ↓ LOEC>100 25 ↓ LOEC>50 50 ↓ LOEC>100 50 ↓ LOEC>50

Vtg 25 ↑ 6.25↑ 6.25 ↑ 6.25 ↑

Gonad 

Phenotype

100? LOEC>100 LOEC>50 LOEC>50

Fecundity 100 ↓ LOEC>50

Fertility 100 ↓ LOEC>50

Highest 

Conc

100 50 100 100 50

4tOP MMT LOEC Summary 4tOP (ug/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult (8 wpf) subadult (8 wpf) adult (15 wpf) adult (15 wpf) adult (15 wpf) 1 0 na

XY XX XY XX XY XX XY XX XY XX 2 6.25 na

Weight LOEC>100 LOEC>50 3 12.5 na

Length LOEC>100 LOEC>50 4 25 na

Survival LOEC>100 LOEC>50 LOEC>100 LOEC>100 LOEC>50 LOEC>50 5 50 na

Hatch LOEC>100 LOEC>50 6 100 na

Papillae 6.25 ↓ LOEC>100 LOEC>50 LOEC>50 50 ↓ LOEC>100 50 ↓ LOEC>50

Vtg 12.5 ↑ 6.25↑ 6.25 ↑ 6.25 ↑

Gonad 

Phenotype

100? LOEC>100 LOEC>50 LOEC>50

Fecundity 100 ↓ LOEC>50

Fertility 100 ↓ LOEC>50

Highest 

Conc

100 50 100 100 50



Original Incorrect Summary Table (Table 1) for CMP MED (Appendix H, page 83).

Corrected Summary Table (Table 1) for CMP MED (Appendix H, page 83).

CMP MMT LOEC Summary CMP (ug/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

Subadult (8 wpf) Subadult (8 wpf) Adult (16 wpf) Adult (16 wpf) Adult (16 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 21 5

Weight JT:165 ↓ LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 3 43 14

Length JT:165 ↓ LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 4 88 28

Survival LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 5 165 22

Hatch LOEC > 345 LOEC > 345 6 345 74

Papillae LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345

Vtg LOEC > 345 LOEC > 345 LOEC > 345 JT:345 ↓ LOEC > 345 JT:88 ↑ LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345

Gonad Phenotype LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345

Fecundity LOEC > 345 LOEC > 345 LOEC > 345

Fertility LOEC > 345 LOEC > 345 LOEC > 345

Highest Conc 345 345 345 345

CMP MMT LOEC Summary CMP (ug/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

Subadult (8 wpf) Subadult (8 wpf) Adult (16 wpf) Adult (16 wpf) Adult (16 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 21 5

Weight LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 3 43 14

Length LOEC > 345 LOEC > 345 LOEC > 345 345 ↓ LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 4 88 28

Survival LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 5 165 22

Hatch LOEC > 345 LOEC > 345 6 345 74

Papillae LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345

Vtg LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 JT:88 ↑ LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345

Gonad Phenotype LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345 LOEC > 345

Fecundity LOEC > 345 LOEC > 345 LOEC > 345

Fertility LOEC > 345 LOEC > 345 LOEC > 345

Highest Conc 345 345 345 345
CMP F2 Subadult Vitellogenin MED MMT

Concentration (ug/L)

Vtg mRNA Relative to Controls

0 21 43 88 165 345

0

10

20

30

40

50

 XY

 XX

CMP F2 Subadult Vitellogenin MED MMT

Concentration (ug/L)

Vtg mRNA Relative to Controls

0 21 43 88 165 345

0

10

20

30

40

50

 XY

 XX

JT
CMP F1 Subadult Weight MED MMT

Concentration (ug/L)

Body Weight

0 21 43 88 165 345

0

50

100

150

200

250

300

350

400

 XY

 XX

CMP F1 Subadult Weight MED MMT

Concentration (ug/L)

Body Weight

0 21 43 88 165 345

0

50

100

150

200

250

300

350

400

 XY

 XX

JT JT
CMP F1 Subadult Length MED MMT

Concentration (ug/L)

Length

0 21 43 88 165 345

0

5

10

15

20

25

30

 XY

 XX

JT JT

CMP F1 Subadult Length MED MMT

Concentration (ug/L)

Length

0 21 43 88 165 345

0

5

10

15

20

25

30

 XY

 XX
Original Incorrect Summary Table (Table 1) for tamoxifen NIES (Appendix H, page 101).

Tamoxifen MMT LOEC Summary Tamoxifen (ug/L)

F1 F2 F0 F1 Trt Conc S.D.

subadult (54 dpf) subadult (65 dpf) adult adult (92 dpf) 1 0 0

XY XX XY XX XY XX XY XX 2 1.3 0.19

Weight 20↓ 20↓ LOEC>20 20↓ 3 2.5 0.28

Length 20↓ LOEC>20 LOEC>20 20↓ 4 5 0.7

Survival 5 10 1.3

Hatch LOEC>20 LOEC>20 6 20 2.6

SSC 20↓ LOEC>20 1.3↓ LOEC>20 5↑ LOEC>20

Vtg 1.3↑ LOEC>20 1.3↑ 1.3↓ 2.5↑ 5↓

Gonad Phenotype unknown unknown unknown unknown

Fecundity 20↓

Fertility 20↓

Highest Conc 20 20 20 20

Corrected Summary Table (Table 1) for tamoxifen NIES (Appendix H, page 101).

Tamoxifen MMT LOEC Summary Tamoxifen (ug/L)

F1 F2 F0 F1 Trt Conc S.D.

subadult (54 dpf) subadult (65 dpf) adult adult (92 dpf) 1 0 0

XY XX XY XX XY XX XY XX 2 1.3 0.19

Weight LOEC>20 LOEC>20 LOEC>20 LOEC>20 3 2.5 0.28

Length LOEC>20 LOEC>20 LOEC>20 LOEC>20 4 5 0.7

Survival 5 10 1.3

Hatch LOEC>20 LOEC>20 6 20 2.6

SSC 20↓ LOEC>20 1.3↓ LOEC>20 5↑ LOEC>20

Vtg 1.3↑ LOEC>20 2.5 ↑ 1.3↓ 2.5↑ 5↓

Gonad Phenotype unknown unknown unknown unknown

Fecundity 20↓

Fertility 20↓

Highest Conc 20 20 20 20
Tamoxifen F2 Subadult (65 dpf) Vitellogenin NIES MMT

Concentration (ug/L)

Vtg (ng/mg liver)

0 1.3 2.5 5 10 20

0

200

400

600

800

1000

1200

1400

1600

1800

2000

2200

2400

TD

JT JT Du JT Du JT Du JT Du

TD

TD

TD

TD

Tamoxifen F2 Subadult (65 dpf) Vitellogenin NIES MMT

Concentration (ug/L)

Vtg (ng/mg liver)

0 1.3 2.5 5 10 20

0

200

400

600

800

1000

1200

1400

1600

1800

2000

2200

2400

TD

JT JT Du JT Du JT Du JT Du

TD

TD

TD

TD

*

* *

*

*

* * *

*
Tamoxifen F1 Subadult (54 dpf) Weight NIES MMT

Concentration (ug/L)

Weight (g)

0 1.3 2.5 5 10 20

0.00

0.02

0.04

0.06

0.08

0.10

0.12

0.14

0.16

0.18

0.20

 XX

 XY

Du

TD

JT

JT

Tamoxifen F1 Subadult (54 dpf) Weight NIES MMT

Concentration (ug/L)

Weight (g)

0 1.3 2.5 5 10 20

0.00

0.02

0.04

0.06

0.08

0.10

0.12

0.14

0.16

0.18

0.20

 XX

 XY

Du

TD

JT

JT
Tamoxifen F2 Subadult (65 dpf) Weight NIES MMT

Concentration (ug/L)

Weight (g)

0 1.3 2.5 5 10 20

0.00

0.05

0.10

0.15

0.20

0.25

0.30

0.35

0.40

 XX

 XY

TD JT

Tamoxifen F2 Subadult (65 dpf) Weight NIES MMT

Concentration (ug/L)

Weight (g)

0 1.3 2.5 5 10 20

0.00

0.05

0.10

0.15

0.20

0.25

0.30

0.35

0.40

 XX

 XY

TD JT
Tamoxifen F1 Subadult (54 dpf) Length NIES MMT

Concentration (ug/L)

Length (mm)

0 1.3 2.5 5 10 20

0

2

4

6

8

10

12

14

16

18

20

22

24

26

 XX

 XY

Du

Tamoxifen F1 Subadult (54 dpf) Length NIES MMT

Concentration (ug/L)

Length (mm)

0 1.3 2.5 5 10 20

0

2

4

6

8

10

12

14

16

18

20

22

24

26

 XX

 XY

Du
Tamoxifen F2 Subadult (65 dpf) Length NIES MMT

Concentration (ug/L)

Length (mm)

0 1.3 2.5 5 10 20

0

5

10

15

20

25

30

 XX

 XY

Du JT

Tamoxifen F2 Subadult (65 dpf) Length NIES MMT

Concentration (ug/L)

Length (mm)

0 1.3 2.5 5 10 20

0

5

10

15

20

25

30

 XX

 XY

Du JT
Original Incorrect Summary Table (Table 1) for trenbolone MED (Appendix H, page 120).

Corrected Summary Table (Table 1) for trenbolone MED (Appendix H, page 118).

Trenbolone MMT LOEC Summary

Trenbolone 

(ng/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

Subadult (8 wpf) Subadult (8 wpf) Adult (16 wpf) Adult (16 wpf) Adult (16 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 2 0.5

Weight LOEC>84 Du:32 ↓ LOEC>13 LOEC>13 LOEC>84 D,JT:84 ↑ LOEC>84 LOEC>84 LOEC>13 LOEC>13 3 5 1.2

Length LOEC>84 LOEC>84 LOEC>13 LOEC>13 LOEC>84 LOEC>84 LOEC>84 LOEC>84 LOEC>13 LOEC>13 4 13 2.7

Survival LOEC>84 LOEC>84 LOEC>13 LOEC>13 LOEC>84 LOEC>84 LOEC>84 LOEC>84 LOEC>13 LOEC>13 5 32 4.8

Hatch LOEC>84 LOEC>13 6 84 12.9

Papillae LOEC>84 Du,JT:32 ↑ LOEC>13 LOEC>13 LOEC>84 Du,JT:84 ↑ LOEC>84 Du,JT:84 ↑ LOEC>13 LOEC>13

Vtg LOEC>84 Du,JT:32 ↓ LOEC>13 LOEC>13 LOEC>84 LOEC>84 JT:32 ↓ D:84 ↓ LOEC>13 LOEC>13

Gonad 

Phenotype LOEC>84 32 ↑ LOEC>13 LOEC>13 LOEC>84 LOEC>84 LOEC>84 84 ↑ LOEC>13 LOEC>13

Fecundity 84 ↓ 32 ↓ LOEC>13

Fertility 84 ↓ 32 ↓ LOEC>13

Highest Conc 84 13 84 84 13

Trenbolone MMT LOEC Summary

Trenbolone 

(ng/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

Subadult (8 wpf) Subadult (8 wpf) Adult (16 wpf) Adult (16 wpf) Adult (16 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 2 0.5

Weight LOEC>84 D:84 ↓ LOEC>13 LOEC>13 LOEC>84 D,JT:84 ↑ LOEC>84 LOEC>84 LOEC>13 LOEC>13 3 5 1.2

Length LOEC>84 LOEC>84 LOEC>13 LOEC>13 LOEC>84 LOEC>84 LOEC>84 LOEC>84 LOEC>13 LOEC>13 4 13 2.7

Survival LOEC>84 LOEC>84 LOEC>13 LOEC>13 LOEC>84 LOEC>84 LOEC>84 LOEC>84 LOEC>13 LOEC>13 5 32 4.8

Hatch LOEC>84 LOEC>13 6 84 12.9

Papillae LOEC>84 D:32 ↑ LOEC>13 LOEC>13 LOEC>84 Du,JT:84 ↑ LOEC>84 Du,JT:84 ↑ LOEC>13 LOEC>13

Vtg LOEC>84 D:84 ↓ LOEC>13 LOEC>13 LOEC>84 LOEC>84 JT:32 ↓ D:84 ↓ LOEC>13 LOEC>13

Gonad 

Phenotype LOEC>84 32 ↑ LOEC>13 LOEC>13 LOEC>84 LOEC>84 LOEC>84 84 ↑ LOEC>13 LOEC>13

Fecundity 84 ↓ 32 ↓ LOEC>13

Fertility 84 ↓ 32 ↓ LOEC>13

Highest Conc 84 13 84 84 13
Trenbolone F1 Subadult Vitellogenin MED MMT

Concentration (ng/L)

Vtg mRNA Relative to Controls

0 2 5 13 32 84

0

2

4

6

8

10

 XY

 XX

Du,JT

Du,JT

Trenbolone F1 Subadult Vitellogenin MED MMT

Concentration (ng/L)

Vtg mRNA Relative to Controls

0 2 5 13 32 84

0

2

4

6

8

10

 XY

 XX

Du,JT

Du,JT *
Trenbolone F1 Subadult Weight MED MMT

Concentration (ng/L)

Body Weight (mg)

0 2 5 13 32 84

0

50

100

150

200

250

300

350

400

 XY

 XX

Du

Du

Trenbolone F1 Subadult Weight MED MMT

Concentration (ng/L)

Body Weight (mg)

0 2 5 13 32 84

0

50

100

150

200

250

300

350

400

 XY

 XX

Du

Du*
Original Incorrect Summary Table (Table 1) for prochloraz MED (Appendix H, page 140).

Corrected Summary Table (Table 1) for prochloraz MED (Appendix H, page 137).

Prochloraz MMT LOEC Summary Prochloraz (μg/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult (8 wpf) subadult (8 wpf) adult (16 wpf) adult (16 wpf) adult (16 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 5 1

Weight 9 ↓ 9 ↓ 5 ↓ 9 ↓ LOEC>41 41↑ LOEC>25 LOEC>25 LOEC>25 LOEC>25 3 9 2

Length 9 ↓ 9 ↓ 9 ↓ 9 ↓ LOEC>41 9 ↑ 25 ↓ 25 ↓ LOEC>25 LOEC>25 4 17 3

Survival LOEC>25 25 ↓ LOEC>41 LOEC>41 LOEC>25 LOEC>25 LOEC>25 LOEC>25 5 25 4

Hatch 25 ↓ LOEC>25 6 41 3

Papillae 9 ↓ LOEC>25 LOEC>25 LOEC>25 LOEC>41 LOEC>41 LOEC>25 LOEC>25 LOEC>25 LOEC>25

Vtg LOEC>25 9 ↓ LOEC>25 9 ↓

Gonad 

Phenotype LOEC>25 LOEC>25 LOEC>25 LOEC>25 LOEC>41 LOEC>41 LOEC>25 LOEC>25 LOEC>25 LOEC>25

Fecundity 41 ↓ LOEC > 25 25 ↓

Fertility 41 ↓ LOEC > 25 25 ↓

Highest Conc 25/41 17/25 41 25 25

Prochloraz MMT LOEC Summary Prochloraz (μg/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

subadult (8 wpf) subadult (8 wpf) adult (16 wpf) adult (16 wpf) adult (16 wpf) 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 5 1

Weight 9 ↓ 9 ↓ LOEC>25 9 ↓ LOEC>41 41↑ LOEC>25 LOEC>25 LOEC>25 LOEC>25 3 9 2

Length 9 ↓ 9 ↓ LOEC>25 5 ↓ LOEC>41 9 ↑ 25 ↓ 25 ↓ LOEC>25 LOEC>25 4 17 3

Survival LOEC>25 25 ↓ LOEC>41 LOEC>41 LOEC>25 LOEC>25 LOEC>25 LOEC>25 5 25 4

Hatch 25 ↓ LOEC>25 6 41 3

Papillae 9 ↓ LOEC>25 9 ↓ LOEC>25 LOEC>41 LOEC>41 LOEC>25 LOEC>25 LOEC>25 LOEC>25

Vtg LOEC>25 9 ↓ LOEC>25 9 ↓

Gonad 

Phenotype LOEC>25 LOEC>25 LOEC>25 LOEC>25 LOEC>41 LOEC>41 LOEC>25 LOEC>25 LOEC>25 LOEC>25

Fecundity 41 ↓ LOEC > 25 25 ↓

Fertility 41 ↓ LOEC > 25 25 ↓

Highest Conc 25/41 17/25 41 25 25
Prochloraz-MED MMT F2 Subadult SSC

Concentration (ug/L)

Anal Fin Papillae (#/fin)

0 5 9 17

0

20

40

60

80

100

 XY

 XX

 Individual Fish

Prochloraz-MED MMT F2 Subadult SSC

Concentration (ug/L)

Anal Fin Papillae (#/fin)

0 5 9 17

0

20

40

60

80

100

 XY

 XX

 Individual Fish

D

D
Prochloraz-MED MMT F2 Subadult Weight

Concentration (ug/L)

Body Weight (ug/L)

0 5 9 17

0

50

100

150

200

250

300

350

400

 XY

 XX

D

D D

D D

Prochloraz-MED MMT F2 Subadult Weight

Concentration (ug/L)

Body Weight (ug/L)

0 5 9 17

0

50

100

150

200

250

300

350

400

 XY

 XX

D

D D

D D
Prochloraz-MED MMT F2 Subadult Length

Concentration (ug/L)

Length (mm)

0 5 9 17

0

5

10

15

20

25

30

35

40

 XX

 XY

JT

JT JT

JT

Prochloraz-MED MMT F2 Subadult Length

Concentration (ug/L)

Length (mm)

0 5 9 17

0

5

10

15

20

25

30

35

40

 XX

 XY

JT

JT JT

JT

* D

D
Original Incorrect Summary Table (Table 1) for vinclozolin MED (Appendix H, page 163).

Corrected Summary Table (Table 1) for vinclozolin MED (Appendix H, page 160).

Vinclozolin MMT MED LOEC Summary

Vinclolozlin 

(μg/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

Subadult (9 wpf) Subadult (9 wpf) Adult (15 wpf) Adult (15 wpf) Adult 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 17 2

Weight LOEC>136 LOEC>253 LOEC>136 LOEC>136 33↑(JT) 253↑(JT) LOEC>136 70↑(JT) 3 33 3

Length LOEC>136 LOEC>253 LOEC>136 LOEC>136 253↑(JT) LOEC>253 LOEC>136 70↑(JT) 4 70 6

Survival 253↓ LOEC>136 LOEC>253 LOEC>253 LOEC>136 LOEC>253 5 136 18

Hatch 253↓ need stats LOEC>136 6 253 59

Papillae 17↓(JT) LOEC>253 33↓(JT) LOEC>136 LOEC>253 LOEC>253 LOEC>136 LOEC>253

Vtg LOEC>136 LOEC>253 136↑(JT) LOEC>136

Gonad 

Phenotype LOEC>136 LOEC>253 LOEC>136 LOEC>136 LOEC>136 LOEC>253

Fecundity 17↓(in 3rd week) LOEC>136 

Fertility LOEC>253(=fecundity) LOEC>136 

Highest 

Conc 136/253 136 253 136/253

Vinclozolin MMT MED LOEC Summary

Vinclolozlin 

(μg/L)

F1 F2 F0 F1 F2 Trt Conc S.D.

Subadult (9 wpf) Subadult (9 wpf) Adult (15 wpf) Adult (15 wpf) Adult 1 0 0

XY XX XY XX XY XX XY XX XY XX 2 17 2

Weight LOEC>136 LOEC>253 LOEC>136 LOEC>136 33↑(JT) 253↑(JT) LOEC>136 70↑(JT) 3 33 3

Length LOEC>136 LOEC>253 LOEC>136 LOEC>136 253↑(JT) LOEC>253 LOEC>136 70↑(JT) 4 70 6

Survival 253↓ LOEC>136 LOEC>253 LOEC>253 LOEC>136 LOEC>253 5 136 18

Hatch 253↓ LOEC>136 6 253 59

Papillae 33↓ LOEC>253 33↓ LOEC>136 LOEC>253 LOEC>253 LOEC>136 LOEC>253

Vtg 33↑ LOEC>253 136↑ LOEC>136

Gonad 

Phenotype LOEC>136 LOEC>253 LOEC>136 LOEC>136 LOEC>136 LOEC>253

Fecundity 17↓(in 3rd week) LOEC>136 

Fertility LOEC>253(=fecundity) LOEC>136 

Highest 

Conc 136/253 136 253 136/253
Vinclozolin F1 Subadult Vitellogenin MED MMT

Concentration (ug/L)

Vtg mRNA Relative to Controls

0 17 33 70 136 253

0

500

1000

1500

2000

2500

3000

3500

 XY

 XX

Vinclozolin F1 Subadult Vitellogenin MED MMT

Concentration (ug/L)

Vtg mRNA Relative to Controls

0 17 33 70 136 253

0

500

1000

1500

2000

2500

3000

3500

 XY

 XX

D
Vinclozolin F1 Subadult SSC MED MMT

Concentration (ug/L)

Anal Fin Papillae (#/fin)

0 17 33 70 136 253

0

20

40

60

80

100

120

140

 XY

 XX

JT

JT

Vinclozolin F1 Subadult SSC MED MMT

Concentration (ug/L)

Anal Fin Papillae (#/fin)

0 17 33 70 136 253

0

20

40

60

80

100

120

140

 XY

 XX

JT

JT

D
Original Incorrect Summary Table (Table 1) for vinclozolin interlab Lab 1 (Appendix C, page 5).

Vinclozolin MMT Lab 1 LOEC Summary Vinclolozlin (μg/L)

F1 F2 F0 F1 Trt Conc S.D.

Subadult (9 wpf) Subadult (9 wpf) Adult (14 wpf) Adult (14 wpf) 1 0 -

Male Female Male Female Male Female Male Female 2 5 1

Weight 82↑(JT) 82↑(JT) LOEC>197 31↓(JT) 3 13 2

Length 4 31 6

Survival LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197 5 82 10

Hatch LOEC>197 LOEC>197 6 197 29

Papillae 197↓ (JT) LOEC>197 5↓ (JT) LOEC>197 31↓ (D)

Vtg LOEC>197 LOEC>197 LOEC>197 LOEC>197

Gonad Phenotype LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197

Fecundity LOEC>197 LOEC>197

Fertility LOEC>197 LOEC>197

Highest Conc 197 197 197

Corrected Summary Table (Table 1) for vinclozolin interlab Lab 1 (Appendix C, page 5).

Vinclozolin MMT Lab 1 LOEC Summary Vinclolozlin (μg/L)

F1 F2 F0 F1 Trt Conc S.D.

Subadult (9 wpf) Subadult (9 wpf) Adult (14 wpf) Adult (14 wpf) 1 0 -

Male Female Male Female Male Female Male Female 2 5 1

Weight LOEC>197 LOEC>197 LOEC>197 LOEC>197 3 13 2

Length 4 31 6

Survival LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197 5 82 10

Hatch LOEC>197 LOEC>197 6 197 29

Papillae 197↓ LOEC>197 31↓ LOEC>197 31↓ (D)

Vtg LOEC>197 LOEC>197 LOEC>197 LOEC>197

Gonad Phenotype LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197 LOEC>197

Fecundity LOEC>197 LOEC>197

Fertility LOEC>197 LOEC>197

Highest Conc 197 197 197 197
Vinclozolin F2 Subadult SSC ABC Labs MMT

Concentration (ug/L)

Anal Fin Papillae (#/fin)

0 5 13 31 82 197

0

20

40

60

80

100

 Female

 Male

JT

JT

JT

JT

D JT

D

D

D

Vinclozolin F2 Subadult SSC ABC Labs MMT

Concentration (ug/L)

Anal Fin Papillae (#/fin)

0 5 13 31 82 197

0

20

40

60

80

100

 Female

 Male

JT

JT

JT

JT

D JT

D

D

D

Lab 1

Lab 1
Vinclozolin F1 Subadult Weight ABC Labs MMT

Concentration (ug/L)

Weight (mg)

0 5 13 31 82 197

0

50

100

150

200

250

300

350

 Female

 Male

JT

JT JT

JT

Vinclozolin F1 Subadult Weight ABC Labs MMT

Concentration (ug/L)

Weight (mg)

0 5 13 31 82 197

0

50

100

150

200

250

300

350

 Female

 Male

JT

JT JT

JT

Lab 1

Lab 1
Vinclozolin F2 Subadult Weight ABC Labs MMT

Concentration (ug/L)

Weight (mg)

0 5 13 31 82 197

0

50

100

150

200

250

300

350

 Female

 Male

JT

JT

JT

Vinclozolin F2 Subadult Weight ABC Labs MMT

Concentration (ug/L)

Weight (mg)

0 5 13 31 82 197

0

50

100

150

200

250

300

350

 Female

 Male

JT

JT

JT

Lab 1

Lab 1
Original Incorrect Summary Table (Table 1) for vinclozolin Interlab Lab 2 (Appendix C, page 13).

Vinclozolin MMT Lab 2 LOEC Summary Vinclolozlin (μg/L)

F1 F2 F0 F1 Trt Conc S.D.

Subadult (9 wpf) Subadult (9 wpf) Adult (14 wpf) Adult (14 wpf) 1 0 -

XY XX XY XX XY XX XY XX 2 12 6

Weight 62 ↑ (JT) 12 ↑ (JT) 62 ↑ (JT) LOEC>360 LOEC>360 LOEC>360 3 25 9

Length 4 62 19

Survival LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360 5 155 51

Hatch LOEC>360 LOEC>360 6 360 89

Papillae LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360

Vtg LOEC>360 360 ↑ (JT) LOEC>360 LOEC>360

Gonad Phenotype LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360

Fecundity LOEC>360

Fertility LOEC>360

Highest Conc 360 360 360 360

Corrected Summary Table (Table 1) for vinclozolin Interlab Lab 2 (Appendix C, page 13).

Vinclozolin MMT Lab 2 LOEC Summary Vinclolozlin (μg/L)

F1 F2 F0 F1 Trt Conc S.D.

Subadult (9 wpf) Subadult (9 wpf) Adult (14 wpf) Adult (14 wpf) 1 0 -

XY XX XY XX XY XX XY XX 2 12 6

Weight 360 ↑ 360 ↑ LOEC>360 LOEC>360 LOEC>360 LOEC>360 3 25 9

Length 4 62 19

Survival LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360 5 155 51

Hatch LOEC>360 LOEC>360 6 360 89

Papillae LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360

Vtg LOEC>360 LOEC>360 LOEC>360 LOEC>360

Gonad Phenotype LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360 LOEC>360

Fecundity LOEC>360

Fertility LOEC>360

Highest Conc 360 360 360 360
Vinclozolin F1 Subadult Vitellogenin Fort Labs MMT

Concentration (ug/L)

Vtg mRNA (copies per ng RNA)

0 12 25 62 155 360

0

2000

4000

6000

8000

10000

12000

14000

 XY

 XX

JT

Vinclozolin F1 Subadult Vitellogenin Fort Labs MMT

Concentration (ug/L)

Vtg mRNA (copies per ng RNA)

0 12 25 62 155 360

0

2000

4000

6000

8000

10000

12000

14000

 XY

 XX

JT

Lab 2

Lab 2
Vinclozolin F1 Weight Fort Labs MMT

Concentration (ug/L)

Weight (g)

0 12 25 62 155 360

0.00

0.02

0.04

0.06

0.08

0.10

0.12

0.14

0.16

0.18

0.20

0.22

0.24

 XY

 XX

JT

JT

JT

JT JT JT

JT

JT

Vinclozolin F1 Weight Fort Labs MMT

Concentration (ug/L)

Weight (g)

0 12 25 62 155 360

0.00

0.02

0.04

0.06

0.08

0.10

0.12

0.14

0.16

0.18

0.20

0.22

0.24

 XY

 XX

JT

JT

JT

JT JT JT

JT

JT

D

D

Lab 2

Lab 2
Vinclozolin F2 Subadult Weight Fort Labs MMT

Concentration (ug/L)

Weight (g)

0 12 25 62 155 360

0.00

0.02

0.04

0.06

0.08

0.10

0.12

0.14

0.16

0.18

0.20

0.22

0.24

 XY

 XX

JT JT JT

Vinclozolin F2 Subadult Weight Fort Labs MMT

Concentration (ug/L)

Weight (g)

0 12 25 62 155 360

0.00

0.02

0.04

0.06

0.08

0.10

0.12

0.14

0.16

0.18

0.20

0.22

0.24

 XY

 XX

JT JT JT